Meta-analysis of the effects of sodium glucose cotransporter 2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes - PubMed (original) (raw)

. 2020 Dec 7;5(2):219-227.

doi: 10.1002/jgh3.12473. eCollection 2021 Feb.

Affiliations

Meta-analysis of the effects of sodium glucose cotransporter 2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes

Binayak Sinha et al. JGH Open. 2020.

Abstract

Background and aim: Sodium glucose cotransporter 2 inhibitors (SGLT-2i), by way of their unique mode of action, present an attractive strategy for the treatment of type 2 diabetes and non-alcoholic fatty liver disease (NAFLD), which often coexist and may lead to severe complications. However, the evidence for treatment with SGLT-2i is limited to small heterogeneous studies. Therefore, this meta-analysis was conducted to deduce the effects of SGLT-2i in NAFLD with type 2 diabetes (T2D).

Methods: A web-based search identified nine randomized controlled trials from the Cochrane Library, Embase, and PubMed for this meta-analysis. The Comprehensive Meta-Analysis Software version 3 was used to calculate the effect size.

Result: The outcomes of interest were analyzed from a pooled population of 11 369 patients-7281 on SGLT-2i and 4088 in the control arm. SGLT-2i therapy produced a statistically significant improvement in alanine aminotransferase [standardised mean difference (SDM), -0.21, 95% confidence interval (CI), -0.32 to -0.10, P < 0.01], aspartate aminotransferase (Standardised mean difference (SDM), -0.15, 95% CI, -0.24 to -0.07, P < 0.01), and liver fat as measured by proton density fat fraction (SDM, -0.98, 95% CI, -1.53 to -0.44, P < 0.01) in comparison to standard of care or placebo. In addition, there was a significant reduction in glycosylated hemoglobin (SDM, -0.37, 95% CI, -0.60 to -0.14, P < 0.01) and weight (SDM, -0.58, 95% CI, -0.93 to -0.23, P < 0.01) in the SGLT-2i arm.

Conclusion: This meta-analysis provides a convincing signal that SGLT-2i have a salutary effect on NAFLD in type 2 diabetes (T2D), probably driven by an improvement of glycemia and body weight, which in turn attenuates hepatic inflammation and hepatic fat accumulation.

Keywords: alanine aminotransferase; aspartate aminotransferase; liver fat; non‐alcoholic fatty liver disease; sodium glucose cotransporter 2 inhibitors; type 2 diabetes.

© 2020 The Authors. JGH Open: An open access journal of gastroenterology and hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Study selection process.

SGLT

‐2i, sodium glucose cotransporter 2 inhibitors.

Figure 2

Figure 2

Forest plot comparing effect of SGLT‐2i versus control on: (a) alanine aminotransferase (ALT), (b) aspartate aminotransferase (AST), (c) gamma‐glutamyl transferase (GGT). CI, confidence interval; Std, standard.

Figure 3

Figure 3

Forest plot comparing effect of sodium glucose cotransporter 2 inhibitors (SGLT‐2i) versus control on: (a) Liver fat and (b) visceral fat mass (VFM). CI, confidence interval; Std, standard.

Figure 4

Figure 4

Forest plot comparing effect of SGLT‐2i versus control on: (a) weight, (b) triglyceride (TG), and (c) HBA1c. CI, confidence interval; Std, standard.

References

    1. Williamson RM, Price JF, Glancy S et al Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care. 2011; 34: 1139–44. - PMC - PubMed
    1. Sanchez PP, Bril F, Maximos M et al High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J. Clin. Endocrinol. Metab. 2015; 100: 2231–8. - PMC - PubMed
    1. Targher G, Bertolini L, Rodella S et al Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care. 2007; 30: 2119–21. - PubMed
    1. Targher G, Bertolini L, Rodella S et al Non‐alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser‐treated retinopathy in type 2 diabetic patients. Diabetologia. 2008; 51: 444–50. - PubMed
    1. Hazlehurst J, Woods C, Marjot T. Cobbold, Tomlinson J. Non‐alcoholic fatty liver disease and diabetes. Metab. Clin. Exp. 2016; 65: 1096–108. - PMC - PubMed

LinkOut - more resources